Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Metab Toxicol. 2009 Jan;5(1):83-90. doi: 10.1517/17425250802622962 .

Epoprostenol in pulmonary arterial hypertension.

Author information

1
VU University Medical Center, Department of Pulmonology, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

Abstract

BACKGROUND:

Pulmonary arterial hypertension (PAH) is a devastating disease leading to right heart failure and death in a relatively young patient population. In recent years novel PAH specific therapies have become available.

OBJECTIVE:

To determine the place of epoprostenol in current PAH treatment strategies.

METHODS:

An extensive Medline search was performed to evaluate the use of epoprostenol in PAH. Data from both human and animal studies were reviewed.

RESULTS/CONCLUSION:

Epoprostenol is an effective and potent treatment in pulmonary arterial hypertension and has greatly improved survival, exercise capacity, PAH symptoms, pulmonary haemodynamics and disease progression. A main disadvantage is that it can only be delivered through a continuous intravenous pump infusion.

PMID:
19236231
DOI:
10.1517/17425250802622962
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center